Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
Critical Reviews in Oncology/Hematology|November 26, 2022
International consensus on the initial diagnostic workup of cancer of unknown primaryIris van der Strate, Fatemeh Kazemzadeh, Iris D Nagtegaal, et al.
Clinical Lung Cancer|September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II TrialDavid R Spigel, John D Hainsworth, Emily R Burkett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancerMinal Barve, James Bender, Neil Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown PrimaryKanwal Raghav, Hyunsoo Hwang, Alexandre A Jácome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancerDavid Loesch, F Anthony Greco, Neil N Senzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
Pageof 13